関連する実験動画
Updated: Aug 18, 2026

09:42
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
まとめ
組織型プラズミノゲン活性化剤 (t-PA) とウロキナーゼまたは単鎖ウロキナーゼ (scu-PA) の組み合わせは,シナージ的血栓溶解を示します. この組み合わせ治療は,線維素分解を最小限に抑え,用量および全身性線維素分解を減らすことができます.
科学分野:
- バイオケミストリー バイオケミストリー
- 薬理学 薬理学とは
- 心血管研究 循環器科の研究
背景:
- 血栓解消薬療法は,血栓性イベントの治療に不可欠です.
- ウロキナーゼやt-PAのような現在の薬剤は,全身活性化を含む制限があります.
- シナゲティックな組み合わせを研究することで,有効性と安全性が向上する可能性があります.
研究 の 目的:
- 異なるプラズミノゲン活性化剤を組み合わせることで生体内で生じる相乗効果を評価する.
- 結合されたt-PA,scu-PA,およびウロキナーゼの血栓解消効果と全身的効果を比較するために.
主な方法:
- 125Iラベル付きフィブリンを使用したウサギの頸動脈栓塞誘導.
- t-PA,scu-PA,またはウロキナーゼを単独または組み合わせて4時間間にわたって静脈注入します.
- 血栓溶解の定量評価とアルファ2-アンチプラズミンとフィブリノゲン濃度の測定.
主要な成果:
- 個々の薬剤で有意な血栓溶解 (30-60%) が観察されました.
- スクア-PAとt-PAとウロキナゼとの間で,シナギスティック・トロンボリチス効果 (p < .001) が認められた.
- scu-PAとウロキナーゼとの間には,相乗効果が観察されなかった.
- 併用されたt-PAとウロキナーゼは,高用量のウロキナーゼで観察されたアルファ2抗プラズミン消費とフィブリノゲンの分解を引き起こさなかった.
結論:
- t-PAとscu-PAまたはウロキナーゼの組み合わせは,体内において有意な血栓解消作用の相乗効果を示しています.
- この相乗効果のアプローチにより,薬剤の用量を減らすことが可能になります.
- 潜在的に全身のフィブリノリチス活性化と関連するフィブリノゲンの分解を最小限に抑え,治療の安全性を向上させる.
関連する概念動画
Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

